Wedbush analyst Robert Driscoll lowered the firm’s price target on Arvinas to $27 from $43 and keeps a Neutral rating on the shares. The analyst notes the company announced a delay to the initiation of the planned Phase 3 of ARV-471 in combination with CDK4/6 inhibitor palbociclib in 1L ER+/HER2-mBC patients due to a proposed study modification, following observation of an increase in palbociclib exposure in the Phase 1b combination study relative to historical palbociclib PK data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas price target lowered to $95 from $102 at Oppenheimer
- Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
- Wells Fargo downgrades Arvinas to Equal Weight, lowers price target to $49
- Barclays views GSK acquisition interest as positive for oncology stocks
- Arvinas downgraded to Equal Weight from Overweight at Wells Fargo